Sympathetic nervous system alterations with HER2+ antagonism: An early marker of cardiac dysfunction with breast cancer treatment?

ecancermedicalscience

Volumn 8, Issue 1, 2014, Pages

  Lenneman, Carrie G ^a,b   Abdallah, Wissam M ^a   Smith, Holly M ^a   Abramson, Vandana ^a   Mayer, Ingrid A ^a   Silverstein, Cheri ^a,c   Means Powell, Julie ^a   Paranjape, Sachin Y ^a   Lenihan, Daniel ^a   Sawyer, Douglas B ^a,d   Raj, Satish R ^a,d  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b University of Louisville School of Medicine   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardio oncology; Catecholamine; Heart failure; Sympathetic nervous system

Indexed keywords

EID: 84906058904     PISSN: None     EISSN: 17546605     Source Type: Journal    
DOI: 10.3332/ecancer.2014.446     Document Type: Article

References (22)

1. Slamon DJ et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Eng J Med 344 783-92 DOI: 10.1056/NEJM200103153441101 (Pubitemid 32222155)
2. Piccart-Gebhart MJ et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Eng J Med 53 1659-72 DOI: 10.1056/NEJMoa052306 (Pubitemid 41464705)
3. Seidman AD et al (2001) Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification J Clin Oncol 19 2587-95 PMID: 11352950 (Pubitemid 32441364)
4. Yeh ET and Bickford CL (2009) Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management J Am Coll Cardiol 53 2231-47 DOI: 10.1016/j.jacc.2009.02.050 PMID: 19520246
5. Slamon D et al (2011) Adjuvant trastuzumab in HER2-positive breast cancer N Eng J Med 365 1273-83 DOI: 10.1056/NEJMoa0910383
6. Bowles EJ et al (2012) Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study J Natl Cancer Inst 104 1293-305 DOI: 10.1093/jnci/djs317 PMID: 22949432 PMCID: 3433392
7. Kuramochi Y, Guo X, and Sawyer DB (2006) Neuregulin activates erbB2-dependent src/FAK signaling and cytoskeletal remodeling in isolated adult rat cardiac myocytes J Mol Cell Cardiol 41 228-35 DOI: 10.1016/j.yjmcc.2006.04. 007 PMID: 16769082 PMCID: 1847613 (Pubitemid 44080212)
8. Cote GM et al (2005) Neuregulin-1 alpha and beta isoform expression in cardiac microvascular endothelial cells and function in cardiac myocytes in vitro. Exp Cell Res 311 135-46 DOI: 10.1016/j.yexcr.2005.08.017 (Pubitemid 41527182)
9. Matsukawa R et al (2011) Neuregulin-1/ErbB signaling in rostral ventrolateral medulla is involved in blood pressure regulation as an antihypertensive system J Hypertens 29 1735-42 DOI: 10.1097/HJH.0b013e32834937d6 PMID: 21738056
10. Jacob G et al (1997) Effects of volume loading and pressor agents in idiopathic orthostatic tachycardia Circulation 96 575-80 DOI: 10.1161/01.CIR.96.2.575 PMID: 9244228 (Pubitemid 27329436)
11. Geisberg CA et al (2011) Circulating neuregulin-1beta levels vary according to the angiographic severity of coronary artery disease and ischemia Coronary Artery Dis 22 577-82 DOI: 10.1097/MCA.0b013e32834d3346
12. Chen J et al (2012) Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer J Am Coll Cardiol 60 2504-12 DOI: 10.1016/j.jacc.2012.07.068 PMID: 23158536
13. Geisberg CA et al (2013) Circulating neuregulin during the transition from stage a to stage b/c heart failure in a breast cancer cohort J Card Fail 19 10-5 DOI: 10.1016/j.cardfail.2012.11.006 PMID: 23273589 PMCID: 3562720
14. Cardinale D et al (2004) Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy Circulation 109 2749-54 DOI: 10.1161/01.CIR.0000130926.51766.CC PMID: 15148277 (Pubitemid 38737923)
15. Zuppinger C et al (2003) Direct effects on human cardiomyocytes by cancer therapy with monoclonal antibodies to HER2/ erbB2 are not related to apoptosis Circulation 108 IV
16. Kuramochi Y et al (2004) Myocyte contractile activity modulates norepinephrine cytotoxicity and survival effects of neuregulin-1beta Am J Physiol Cell Physiol 286 C222-9 DOI: 10.1152/ajpcell.00312.2003 (Pubitemid 38146345)
17. Cardinale D et al (2010) Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation J Clin Oncol 28 3910-6 DOI: 10.1200/JCO.2009.27.3615 PMID: 20679614
18. Bosch X et al (2013) Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies) J Am Coll Cardiol 61 2355-62 DOI: 10.1016/j.jacc.2013.02.072 PMID: 23583763
19. Kalay N et al (2006) Protective effects of carvedilol against anthracycline-induced cardiomyopathy J Am Coll Cardiol 48 2258-62 DOI: 10.1016/j.jacc.2006.07.052 PMID: 17161256 (Pubitemid 44855419)
20. Ewer MS et al (2005) Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment J Clin Oncol 23 7820-6 DOI: 10.1200/JCO.2005.13.300 PMID: 16258084 (Pubitemid 46657379)
21. Pituskin E et al (2011) Rationale and design of the Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research Trial (MANTICORE 101-Breast): a randomized, placebo-controlled trial to determine if conventional heart failure pharmacotherapy can prevent trastuzumab-mediated left ventricular remodeling among patients with HER2+ early breast cancer using cardiac MRI BMC Cancer 11 318 DOI: 10.1186/1471-2407-11-318
22. Raj SR et al (2009) Propranolol decreases tachycardia and improves symptoms in the postural tachycardia syndrome: less is more Circulation 120 725-34 DOI: 10.1161/CIRCULATIONAHA.108.846501 PMID: 19687359 PMCID: 2758650